<DOC>
	<DOCNO>NCT01968408</DOCNO>
	<brief_summary>AIM : To determine efficacy Lactobacillus reuteri DSM 17938 dose 10 ( 9 ) CFU prevention nosocomial diarrhea . TRIAL DESIGN : Double-blind , placebo control RCT . INTERVENTION : L reuteri DSM 17938 daily dose 10 ( 9 ) CFU . PRIMARY OUTCOME : Nosocomial diarrhoea ( 3 loose watery stool 24 h occur 72 h admission ) .</brief_summary>
	<brief_title>Lactobacillus Reuteri DSM 17938 Preventing Nosocomial Diarrhea Children</brief_title>
	<detailed_description>Nosocomial diarrhea common problem hospitalize child . Previously , document administration L reuteri DSM 17938 dose 10 ( 8 ) colony form unit ( CFU ) compare placebo effect overall incidence nosocomial diarrhea ( Wanke &amp; Szajewska , J Pediatr 2012 ) . Whether high dos L reuteri DSM 17938 effect needs substantiate randomized trial .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<criteria>Children age 148 mo admit hospital reason diarrhea Signed informed consent . Acute gastroenteritis within 3 day admission Symptoms diarrhea suggest gastroenteritis Use probiotic within 7 day admission Immunodeficiency disorder Breastfeeding &gt; 50 % Underlying gastrointestinal tract disorder Malnutrition ( weight/high &lt; 3pc )</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>48 Months</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>nosocomial diarrhea</keyword>
	<keyword>Lactobacillus reuteri DSM 17938</keyword>
	<keyword>rotavirus diarrhea</keyword>
	<keyword>probiotic</keyword>
</DOC>